Petrelintide Phase 2 Update Reports Weight and Glucose Changes in Adults with Type 2 Diabetes

Zealand Pharma's October 7 ZUPREME2 announcement reports up to 9.2% mean weight reduction at 28 weeks, alongside glycemic changes and low gastrointestinal discontinuation rates.

For research use only. Not for human consumption.